Author

Jan Krönke

German Cancer Research CenterORCID 0000-0002-4649-0506Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Philipp MertinsiD· 2 shared Aarthi Nivasini MaheshiD· 1 shared Ahmed M. MamdouhiD· 1 shared Alexandre PuissantiD· 1 shared Benedikt ObermayeriD· 1 shared Brandon Douglas BrowniD· 1 shared Camille LobryiD· 1 shared Cheryl Gek Teng Chan· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Philipp MertinsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Translating multi-omics complexity into sparse prognostic biomarkers for multiple myeloma

Benedikt Obermayer, Manuela Benary, Jan Krönke, Philipp Mertins, Dieter Beule

This paper identifies prognostic biomarkers for multiple myeloma by integrating multi-omics data and shows that proteomic features outperform genomic or transcriptomic data in classification.

bioRxiv · Aug 21, 2026 · PreprintCancer Biology

BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

Ahmed M. Mamdouh, Fang Qi Lim, Yang Mi, Elyse A. Olesinski, Shaista Shabbir Jasdanwala, Xiao Xian Lin, Edward Ayoub, Jordan Yong Ming Tan, Karanpreet Singh Bhatia, Yichen Wang, Shradha Garnaik, Kunal Tomar, Valeriia Sapozhnikova, Cheryl Gek Teng Chan, Chuqi Wang, , Shruti Bhatt

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

bioRxiv · May 17, 2025 · PreprintCancer Biology